Compile Data Set for Download or QSAR
Report error Found 706 Enz. Inhib. hit(s) with all data for entry = 9360
TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461027(US10774053, Compound 148 | US11352329, COMPD # 148)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460910(US10774053, Compound 24 | US11352329, COMPD # 24)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460925(US10774053, Compound 39 | US11352329, COMPD # 39)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460924(US10774053, Compound 38 | US11352329, COMPD # 38)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461088(US10774053, Compound 281 | US11352329, COMPD # 281)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461185(US10774053, Compound 235 | US11352329, COMPD # 235)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460922(US10774053, Compound 36 | US11352329, COMPD # 36)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460904(US10774053, Compound 18 | US11352329, COMPD # 18)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460903(US10774053, Compound 17)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461116(US10774053, Compound 289 | US11352329, COMPD # 289)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460936(US10774053, Compound 49 | US11352329, COMPD # 49)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461115(US10774053, Compound 340 | US11352329, COMPD # 340)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460918(US10774053, Compound 32 | US11352329, COMPD # 32)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461227(US10774053, Compound 265 | US11352329, COMPD # 265)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460917(BDBM556558 | US10774053, Compound 31)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461194(US10774053, Compound 241 | US11352329, COMPD # 241)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461193(US10774053, Compound 240 | US11352329, COMPD # 240)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460898(US10774053, Compound 12 | US11352329, COMPD # 12)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460932(US10774053, Compound 45 | US11352329, COMPD # 45)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460965(US10774053, Compound 85 | US11352329, COMPD # 85)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461208(US10774053, Compound 252 | US11352329, COMPD # 252)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460914(US10774053, Compound 28)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460896(US10774053, Compound 10 | US11352329, COMPD # 10)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460930(US10774053, Compound 43 | US11352329, COMPD # 43)
Affinity DataIC50: 1.70nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461052(US10774053, Compound 185 | US11352329, COMPD # 185)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460919(US10774053, Compound 33 | US11352329, COMPD # 33)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460927(US10774053, Compound 41 | US11352329, COMPD # 41)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460961(US10774053, Compound 81 | US11352329, COMPD # 81)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461114(US10774053, Compound 339 | US11352329, COMPD # 339)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460967(US10774053, Compound 87 | US11352329, COMPD # 87)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460974(US10774053, Compound 94 | US11352329, COMPD # 94)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460905(US10774053, Compound 19 | US11352329, COMPD # 19)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461030(US10774053, Compound 151 | US11352329, COMPD # 151)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460913(US10774053, Compound 27)
Affinity DataIC50: 1.80nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461044(US10774053, Compound 178 | US11352329, COMPD # 178)
Affinity DataIC50: 1.90nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461043(US10774053, Compound 177 | US10774053, Compound 25...)
Affinity DataIC50: 1.90nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461195(US10774053, Compound 242 | US11352329, COMPD # 242)
Affinity DataIC50: 1.90nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461186(US10774053, Compound 236 | US11352329, COMPD # 236)
Affinity DataIC50: 1.90nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460972(US10774053, Compound 92 | US11352329, COMPD # 92)
Affinity DataIC50: 1.90nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460979(US10774053, Compound 99 | US11352329, COMPD # 99)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461108(US10774053, Compound 288 | US11352329, COMPD # 288)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460911(US10774053, Compound 25 | US11352329, COMPD # 25)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461056(US10774053, Compound 189 | US11352329, COMPD # 189)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461119(US10774053, Compound 292 | US11352329, COMPD # 292)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461216(US10774053, Compound 256 | US11352329, COMPD # 256)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460989(US10774053, Compound 111 | US11352329, COMPD # 111)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460955(US10774053, Compound 75 | US11352329, COMPD # 75)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460970(US10774053, Compound 90 | US11352329, COMPD # 90)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461051(US10774053, Compound 184 | US11352329, COMPD # 184)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM461034(US10774053, Compound 155 | US11352329, COMPD # 155)
Affinity DataIC50: 2nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

Displayed 1 to 50 (of 706 total ) | Next | Last >>
Jump to: